New lung drug aims to slow scarring in IPF patients
Disease control
Ongoing
This phase 2 trial tests a new drug called LYT-100 (deupirfenidone) in 240 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing difficulty. Participants receive either LYT-100, the existing drug pirfenidone, or a placebo. The main goa…
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC